SHP Share Price

Open 3840.00 Change Price %
High 3842.50 1 Day -106.50 -2.75
Low 3738.50 1 Week -43.00 -1.13
Close 3764.50 1 Month -406.00 -9.74
Volume 2171107 1 Year -1265.50 -25.16
52 Week High 5377.00
52 Week Low 3738.50
SHP Important Levels
Resistance 2 3860.91
Resistance 1 3821.18
Pivot 3781.83
Support 1 3707.82
Support 2 3668.09
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 63.91 -0.76%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 22.54 61.00%
BAC 22.54 61.00%
BAC 22.54 61.00%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

Shire PLC (LON: SHP)

SHP Technical Analysis 5
As on 18th Aug 2017 SHP Share Price closed @ 3764.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4609.66 & Strong Sell for SHORT-TERM with Stoploss of 4216.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
SHP Target for August
1st Target up-side 4480.91
2nd Target up-side 4635.04
3rd Target up-side 4789.18
1st Target down-side 4041.09
2nd Target down-side 3886.96
3rd Target down-side 3732.82
SHP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.shire.com
SHP Address
SHP
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland
Phone: 353 1 429 7700
SHP Latest News
Shire plc – American Depositary (SHPG) Position Increased by Afam Capital, Inc.   Modern Readers   - 18th Aug 17
Shire PLC (SHP): Looking To Captalise On Unmet Needs In Eye Care   Simply Wall St   - 16th Aug 17
Market Risers: Shire PLC, Standard Chartered PLC, Tesco PLC   DirectorsTalk Interviews   - 15th Aug 17
Shire seeks European marketing approval for dry eye drops   Proactive Investors UK   - 15th Aug 17
Why Corporate Spinoffs For Shire And Valeant Make Sense   Seeking Alpha   - 05th Aug 17
Shire Q2/2017: Market Reaction Makes No Sense   Seeking Alpha   - 05th Aug 17
Shire Plc (SHPG) Q2 2017 Results - Earnings Call Transcript   Seeking Alpha   - 04th Aug 17
Earnings Reaction History: Shire plc, 33.3% Follow-Through Indicator, 2.9 ...   Nasdaq   - 03rd Aug 17
Shire plc : Total voting rights   GlobeNewswire (press release)   - 01st Aug 17
Don't Lose The Faith In Shire   Seeking Alpha   - 26th Jul 17
Interactive Technical Analysis Chart Shire PLC ( SHP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Shire PLC
SHP Business Profile
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.